What additional work‑up is indicated for an asymptomatic adult with a platelet count of 406 × 10⁹/L?

Work-up for Platelet Count of 406 × 10⁹/L

For an asymptomatic adult with a platelet count of 406 × 10⁹/L, repeat the complete blood count with differential and peripheral blood smear to confirm persistent thrombocytosis, then pursue targeted testing based on clinical context to distinguish reactive (secondary) thrombocytosis from primary myeloproliferative neoplasms.

Initial Confirmation and Assessment

The first step is confirming this is true thrombocytosis (defined as platelet count ≥450 × 10⁹/L by most guidelines, though your value of 406 is borderline elevated) 1. Since most thrombocytosis is reactive and transient, repeat the CBC with differential in 2-4 weeks to document persistence before pursuing extensive work-up.

During the repeat testing, obtain a peripheral blood smear to evaluate:

• Other cell lines for abnormalities suggesting myeloproliferative neoplasms
• Platelet morphology
• Presence of left-shifted granulopoiesis or immature cells
• Evidence of iron deficiency (which commonly causes reactive thrombocytosis)

Distinguishing Reactive from Primary Thrombocytosis

Screen for Common Reactive Causes

If thrombocytosis persists, obtain:

• C-reactive protein (CRP) - elevated in inflammatory conditions 1
• Iron studies with ferritin - iron deficiency is a frequent cause of reactive thrombocytosis 1
• Review for clinical evidence of:
  • Active infection or inflammation
  • Malignancy (solid tumors commonly cause reactive thrombocytosis)
  • Recent surgery or trauma
  • Hemolysis
  • Medications (epinephrine, all-trans retinoic acid)
  • Tissue damage

When to Suspect Primary Thrombocytosis

Consider essential thrombocythemia or other myeloproliferative neoplasms if:

• Platelet count persistently >450 × 10⁹/L without identified secondary cause
• Splenomegaly on examination
• Symptoms of microvascular occlusion (headaches, paresthesias, erythromelalgia)
• History of unexplained thrombosis or bleeding
• Abnormalities in other cell lines (leukocytosis, left shift)

Work-up for Suspected Essential Thrombocythemia

If secondary causes are excluded and thrombocytosis persists, proceed with:

1. JAK2 V617F mutation testing (positive in ~60% of essential thrombocythemia) 1

2. If JAK2 negative, test for:

   • CALR (calreticulin) mutations (positive in ~25% of cases)
   • MPL (myeloproliferative leukemia) mutations (positive in ~3% of cases)

3. Bone marrow biopsy with cytogenetics - required for definitive diagnosis even with positive molecular markers 1

The bone marrow will show:

• Increased megakaryocyte proliferation with enlarged, mature forms
• Absence of increased reticulin fibrosis (distinguishes from myelofibrosis)
• Exclusion of BCR-ABL1 (to rule out chronic myeloid leukemia) 2
• Absence of features suggesting polycythemia vera or primary myelofibrosis

Critical Pitfalls to Avoid

Do not over-investigate at platelet count of 406 × 10⁹/L - this is only mildly elevated and most likely reactive. The threshold for concern is typically ≥450 × 10⁹/L, and even then, secondary causes account for the vast majority of cases 1.

Do not assume thrombocytosis requires treatment - in reactive thrombocytosis, treat the underlying condition. Even in essential thrombocythemia, asymptomatic patients with platelet counts <1000-1500 × 10⁹/L and no high-risk features may only require observation with low-dose aspirin 3, 4.

Do not miss iron deficiency - this is one of the most common causes of reactive thrombocytosis and is easily correctable. However, note that iron supplementation may paradoxically worsen thrombocytosis initially 5.

Do not forget cardiovascular risk assessment - if essential thrombocythemia is diagnosed, calculate the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia to stratify risk and guide management 1.

Practical Algorithm

For platelet count 406 × 10⁹/L:

1. Repeat CBC with differential and smear in 2-4 weeks
2. If persistent and >450 × 10⁹/L → Check CRP, ferritin, iron studies
3. If inflammatory markers elevated → investigate infection, inflammation, malignancy
4. If iron deficient → replace iron, recheck platelets
5. If no secondary cause identified → JAK2, CALR, MPL testing
6. If molecular markers positive OR unexplained persistent thrombocytosis → bone marrow biopsy
7. If essential thrombocythemia confirmed → risk stratify and consider aspirin ± cytoreduction based on age >60 years, prior thrombosis, or platelet count >1000-1500 × 10⁹/L 5, 3